9 December 2020
AstraZeneca and the University of Oxford have published interim data from the UK and Brazil Phase III trials of their Covid-19 vaccine candidate, AZD1222. These results, which were published in a peer-reviewed article in The Lancet, confirmed that AZD1222 was 70.4% effective at preventing symptomatic Covid-19 when results from two different dosing regimens were pooled. The data also showed that AZD1222 was safe and was effective at preventing severe Covid-19 disease.
Cyxone announced has received regulatory approval from Poland‘s ethics committee to commence a Phase II clinical trial of Rabeximod among Covid-19 patients suffering with moderate symptoms. The oral treatment aims to prevent disease progression and acute respiratory distress symptoms (ARDS) in Covid-19 patients.
HALIX and AstraZeneca are collaborating on large-scale commercial manufacturing of AZD1222, an adenovirus vector-based Covid-19 vaccine developed by the University of Oxford. Under the terms of the agreement, HALIX will carry out commercial manufacturing of the vaccine at its cGMP facility in the Netherlands.
Indian vaccine and pharmaceutical company Biological E and the Ohio State Innovation Foundation (OSIF) have signed an exclusive license agreement for a Covid-19 vaccine technology. OSIF licensed the novel live attenuated recombinant measles virus (rMeV)-based vaccine approaches and candidates to fight the SARS-CoV-2 virus to Biological E. The technology was invented by Ohio State University‘s College of Veterinary Medicine.
Moderna announced that the Swiss Federal Government has increased its purchase commitment order for Moderna’s mRNA-1273 vaccine from 4.5 million to 7.5 million doses. Moderna is most likely to transport the Covid-19 vaccine as early as December if regulatory approval is achieved during the month. Swissmedic has started a rolling review progress of the company’s mRNA vaccine.